Loading clinical trials...

Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia | Clinical Trials | Clareo Health

COMPLETEDNA

Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia

NCT00005892•Fairview University Medical Center

View on ClinicalTrials.gov

Summary

OBJECTIVES: I. Determine the effectiveness of moderate dose cyclophosphamide and radiotherapy in terms of improving survival and reducing the morbidity following allogeneic bone marrow transplantation in patients with myelodysplastic syndrome and acute leukemia related to Fanconi's anemia.

Detailed Description

PROTOCOL OUTLINE: Patients receive cyclophosphamide IV over 1-2 hours on day -6 through -3 and total body radiotherapy on day -1. Patients undergo allogeneic bone marrow transplantation on day 0.

Eligibility

Age

0 - 54 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of Fanconi's anemia with the family history and typical phenotype including: Short stature Hypoplastic radii Skin pigmentation Renal anomalies Chromosomal fragility
•Evidence of Fanconi's myelodysplastic syndrome Bone marrow dysplasia of all 3 marrow cell lines AND Clonal cytogenetic abnormalities demonstrable in marrow cells
•First complete remission following therapy for Fanconi's acute leukemia allowed
•Must have related histocompatible donor No evidence of excessive in vitro chromosome fragility typical of Fanconi's anemia Normal CBC and bone marrow

Locations (1)

Fairview University Medical Center

Minneapolis, Minnesota, United States

Key Dates

Start Date

March 1, 2000

Last Updated

June 24, 2005

Conditions

Fanconi's AnemiaMyelodysplastic SyndromesLeukemia, Nonlymphocytic, AcuteLeukemia, Lymphocytic, Acute

Interventions

cyclophosphamide

DRUG

Allogeneic Bone Marrow Transplantation

PROCEDURE

Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS

NCT07270978

Acute Myeloid LeukemiaMyelodysplastic Syndromes+1 more

View study

RECRUITINGPHASE1

Venetoclax Basket Trial for High Risk Hematologic Malignancies

NCT05292664

Myelodysplastic Syndromes, de NovoMyelodysplastic Syndromes, Secondary+9 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 24, 2005Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia

Inclusion Criteria

Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS

Venetoclax Basket Trial for High Risk Hematologic Malignancies

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS